What is the fine-grained topic of the following text: Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE. Only return the topic.
Study comparing Trastuzumab Emtansine and Trastuzumab as adjuvant therapy in HER2-positive early breast cancer patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy.